Dung Nguyen, MD, PharmD
Palo Alto, California, 94304, United States
Location status: Recruiting
NCT Number: NCT04888975
To evaluate the Dayspring Active Wearable Compression Technology in enhancing lymph movement and its safety and effectiveness after lymphatic surgery
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Palo Alto, California, 94304, United States
Location status: Recruiting
To evaluate the Dayspring Active Wearable Compression Technology in enhancing lymph movement and its safety and effectiveness after lymphatic surgery
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dayspring Active Wearable Compression System
Time frame: Baseline and at Day 28
ICG fluorescence lymphatic imaging evaluates for changes in lymphatic drainage of the limb. ICG is a water soluble tricarbocyanine dye, has a short plasma half life of 3 to 5 minutes in humans, is excreted exclusively by the liver into the bile, and is not associated with risk for nephrotoxicity. ICG contains sodium iodide and is recommended by manufacturer to be used with caution in patients who have a history of allergy to iodides, although type-I allergic reaction (anaphylaxis) cannot really occur because iodine is a chemical element that is an essential component of the human body.
Contact information is provided by the study sponsor or research team.
Koya Medical, Inc.
Industry
Acronym: TIGRIS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06532955
Breast Cancer Lymphedema, Hemic and Lymphatic Diseases
Maastricht, Limburg, Netherlands
View Trial DetailsNCT06302361
Breast Cancer Lymphedema, Hemic and Lymphatic Diseases
Odense, Region Syddanmark, Denmark
View Trial DetailsNCT05441943
Anastomose, Breast Cancer
Odense, Region Syddanmark, Denmark
View Trial DetailsNCT05142800
Breast Cancer, Breast Cancer Lymphedema
Boston, Massachusetts, United States
View Trial Details